Summary
A new immunotherapy for hepatocellular carcinoma (HCC) using Freund’s adjuvant and recombinant interleukin-2 (IL-2) combined with conventional transarterial chemoembolization therapy was performed. In 16 patients with HCC and one patient with metastatic liver cancer receiving this therapy, decrease and suppression of reelevation of α-fetoprotein after therapy was observed. Disappearance of tumor thrombi of HCC in the main portal vein was observed in a patient, and decrease of carcinoembryonic antigen was also observed in a patient with metastatic liver cancer. The present therapy using Freund’s adjuvant and IL-2 is likely to open a new avenue for the treatment of patients with advanced liver cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Shinagawa T, Ohta M, Kimura K, et al: Clinical features of small hepatocellular carcinomas. Jpn J Gastroenterol 1982;79:2277–2284(in Jpn)
Itai Y, Araki T, Furui S, et al: Differential diagnosis of hepatic masses on computed tomography, with particular reference to hepatocellular carcinoma. J Comput Assist Tomogr 1981;5:834–842
Goldstein HM, Wallace S, Anderson JH, et al: Transcatheter occlusion of abdominal tumors. Radiology 1976;120:539–545
Yamada R, Sato M, Kawabata M, et al: Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983;148:397
Shinagawa T, Ukaji H, Iino Y, et al: Intratumoral injection of absolute ethanol under ultrasound imaging for treatment of small bepatocellular carcinoma. - Attempts in three cases -. Act hepat Jap 1985;26:99–105 (in Jpn)
Rosenberg SA: Adoptive immunotherapy of cancer: Accomplishments and prospects. Cancer Treat Rep 1984;68:233–255
Rosenberg SA, Lotze MT, Muul LM, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metasiatic cancer. N Engl J Med 1985;313:1485–1492
Okuno K, Takagi H, Nakamura T, et al: Treatment for unresectable hepatoma via selective hepatic arterial infusion of lymphokine-activated killer cells generated from autologous spleen cells. Cancer 1986;58:1001–1006
Okuno K, Takagi H, Nakamura T, et al: Treatment for unresectable hepatoma by the selective hepatic arterial infusion of lymphokine-activated killer (LAK) cells generated from autologous spleen cells. Igaku No Ayumi 1985;133:878–879 (in Jpn)
Imawari M, Moriyama T, Matsuhashi N, et al: LAK therapy. Naika 1988;61:675–378(in Jpn)
Freund J: The mode of action of immunologic adjuvants. Adv Tuberc Res 1956;7:130–148
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ito, T., Ikeda, N., Sue, K. et al. Immunotherapy using freund’s adjuvant and recombinant interleukin-2 combined with transarterial chemoembolization for hepatocellular carcinoma. Gastroenterol Jpn 24, 386–392 (1989). https://doi.org/10.1007/BF02774344
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02774344